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Abstract: We examined the effects of the histone deacetylase inhibitor (HDACi) suberoylanilide
hydroxamic acid (SAHA) combined with the vascular endothelial growth factor receptor-1/2 inhibitor
(3Z)-5-hydroxy-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one on MDA-MB-231 breast
cancer cells (triple-negative) in the form of both a cocktail of the separate compounds and a chemically
synthesized hybrid (N-hydroxy-N'-[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-
5-yl]octanediamide). Comparative flow cytometric and Western blot analyses were performed on
cocktail- and hybrid-treated cells to evaluate cell cycle distribution, autophagy/apoptosis modulation,
and mitochondrial metabolic state in order to understand the cellular basis of the cytotoxic effect.
Cell cycle analysis showed a perturbation of the rate of progression through the cycle, with
aspects of redistribution of cells over different cycle phases for the two treatments. In addition,
the results suggest that the two distinct classes of compounds under investigation could induce
cell death by different preferential pathways, i.e., autophagy inhibition (the cocktail) or apoptosis
promotion (the hybrid), thus confirming the enhanced potential of the hybrid approach vs. the
combination approach in finely tuning the biological activities of target cells and also showing the
hybrid compound as an additional promising drug-like molecule for the prevention or therapy of
“aggressive” breast carcinoma.
Keywords: breast cancer; MDA-MB231 cells; histone deacetylase inhibitor; vascular endothelial growth
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1. Introduction
It is generally acknowledged that several signaling pathways are involved in the aggressiveness
and metastatic potential of malignant tumors. Therefore, the multifactorial nature of cancer illustrates
the need for multifunctional therapeutic tools, such as employing the use of more than one compound
to modulate different pathways. Combination therapy has been implemented by combining
compounds in a “cocktail” of two or more unmodified molecules in a single solution, whereas the
production of hybrid compounds is another emerging strategy which has gained popularity in
the last decade [1,2]. In a previous publication, we [3] reported the synthesis of a hybrid drug
(N-hydroxy-N'-[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-5-yl]octanediamide)
based on the merging of fragments of the histone deacetylase inhibitor (HDACi) suberoylanilide
hydroxamic acid (SAHA) and the vascular endothelial growth factor-1 and -2 receptor inhibitor
(VEGFR1/2i) (3Z)-5-hydroxy-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one (Figure 1),
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which was effective in reducing the viability of MDA-MB-231 cells, in an in vitro model system for
triple-negative breast cancer (TNBC).
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endowed with a higher malignant potential than other breast tumor subtypes [4]. Further, the 
limitation of treatment options has prompted the development of novel drugs or analogues of 
pre-existing drugs in the attempt to counteract TNBC cell growth. These compounds, on the other 
hand, necessitate a thorough biological evaluation. Experimental evidence has shown that the  
two parental molecules tested by us [3] are active in restraining MDA-MB-231 cell survival and 
growth. Compound 1 was found to affect the cell cycle and promote apoptosis [5], induce 
polyploidy-dependent senescence [6], and inhibit epidermal growth factor receptor (EGFR) expression, 
thereby disrupting the associated downstream signaling [7]. The combination of 1 with other drugs in 
hybrid anti-cancer molecules has proven to be effective, e.g., as reported by Mendoza-Sanchez et al. [8] 
who developed a bifunctional anti-proliferative 1/estrogen receptor modulator ICI-164,384 
compound active on both TNBC (MDA-MB-231) and estrogen receptor–positive (MCF-7) cells. 
VEGF is a renowned angiogenic growth factor that is recognized by a family of receptor tyrosine 
kinases, the VEGFRs, thereby promoting endothelial cell proliferation and migration [9]. In addition, it 
is known that VEGFRs are able to control the biological behavior of other non-endothelial cytotypes, 
including TNBC cells such as MDA-MB-231, thereby showing the potential to directly monitor 
tumor cell survival and the development of breast cancer [10]. In particular, the inhibition of 
VEGFR2 phosphorylation activity, which is directed to switch on the intracellular signalization of 
phosphatidylInositol 3-kinase (PI3K), AKT and signal transducer and activator of transcription 3 
(STAT3), by the natural products xanthatin (a sesquiterpene lactone) and rhamnazin (an 
O-methylated flavonol), has been shown to significantly inhibit MDA-MB-231 cell growth both in 
culture and in nude mice [11,12]. 
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It is known that, due to a lack of expression of estrogen, progesterone and epidermal growth factor
receptor by TNBC cells, this neoplastic cytotype is extremely “aggressive”; moreover, it is endowed with
a higher malignant potential than other breast tumor subtypes [4]. Further, the limitation of treatment
options has prompted the development of novel drugs or analogues of pre-existing drugs in the attempt
to counteract TNBC cell growth. These compounds, on the other hand, necessitate a thorough biological
evaluation. Experimental evidence has shown that the two parental molecules tested by us [3] are
active in restraining MDA-MB-231 cell survival and growth. Compound 1 was found to affect the cell
cycle and promote apoptosis [5], induce polyploidy-dependent senescence [6], and inhibit epidermal
growth factor receptor (EGFR) expression, thereby disrupting the associated downstream signaling [7].
The combination of 1 with other drugs in hybrid anti-cancer molecules has proven to be effective, e.g.,
as reported by Mendoza-Sanchez et al. [8] who developed a bifunctional anti-proliferative 1/estrogen
receptor modulator ICI-164,384 compound active on both TNBC (MDA-MB-231) and estrogen
receptor–positive (MCF-7) cells. VEGF is a renowned angiogenic growth factor that is recognized by a
family of receptor tyrosine kinases, the VEGFRs, thereby promoting endothelial cell proliferation and
migration [9]. In addition, it is known that VEGFRs are able to control the biological behavior of other
non-endothelial cytotypes, including TNBC cells such as MDA-MB-231, thereby showing the potential
to directly monitor tumor cell survival and the development of breast cancer [10]. In particular,
the inhibition of VEGFR2 phosphorylation activity, which is directed to switch on the intracellular
signalization of phosphatidylInositol 3-kinase (PI3K), AKT and signal transducer and activator of
transcription 3 (STAT3), by the natural products xanthatin (a sesquiterpene lactone) and rhamnazin
(an O-methylated flavonol), has been shown to significantly inhibit MDA-MB-231 cell growth both in
culture and in nude mice [11,12].
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In our previous work [3], both the 1/2 cocktail and compound 3 were shown to be cytotoxic on
TNBC cells with an approximate 1:3 ratio of their half maximal inhibitory concentration (IC50) at
72 h. On the other hand, although comparable in their final effects on MDA-MB-231 cell survival, the
different dose-response curves for the two treatments suggested a likely distinction, at least partially,
of their biochemical and molecular mechanisms of action. Since characterization of the biological
properties of new drugs is a key point for the evaluation of drugs’ potency within the composite
intracellular microenvironment, the present work was aimed at acquiring the initial experimental data
on the functional properties of the compounds under study when administered to MDA-MB-231 cell
cultures through a panel of flow cytometric and immunoblot assays.
2. Results
In order to obtain comparative information on biological parameters of the cytotoxic action
of the 1/2 cocktail and 3 on triple-negative MDA-MB-231 cells, cell cycle state, apoptosis induction
markers (phosphatydilserine externalization and caspase-8 activation), mitochondrial metabolism
and cell redox state markers (mitochondrial transmembrane potential (MMP) and reactive oxygen
species (ROS) production), and autophagy markers (acidic vesicular organelle (AVO) and beclin-1
accumulation) were investigated.
First, MDA-MB-231 cells were examined for distribution of cell cycle phases, and the results
obtained are shown in Figure 2. Exposure to 3 induced a more prominent increase of the G0/G1 phase
fraction than that recorded for the 1/2 cocktail (control vs. 1/2 cocktail = 55.69% vs. 64.05%; control
vs. 3 = 53.68% vs. 78.66%), indicative of a more pronouncedly restrained progression via the S phase
due to the conceivable activation of the corresponding checkpoint. In both experimental conditions, a
similar marked decrease of the S phase fraction (control vs. 1/2 cocktail = 34.11% vs. 10.66%; control
vs. 3 = 36.82% vs. 8%) was observed, a result that appears noteworthy since in breast cancer this
fraction is regarded as prognostic. Moreover, an accumulation of cells in the G2/M phase (control
vs. 1/2 cocktail = 10.2% vs. 25.29%; control vs. 3 = 9.5% vs. 13.34%), more conspicuous for the cocktail
treatment and indicative of the inhibition of cell division, was also recorded.
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Figure 2. Effect of the 1/2 cocktail and 3 on the MDA-MB-231 cell cycle. DNA profiles of MDA-MB-231 
cells following 72 h of culture under control conditions (red line in A,B) and in the presence of either 
10 μM 1/2 cocktail (green line in A) or 29 μM 3 (green line in B). Cell distribution in the different cycle 
phases is reported in the Table (annex). 
Figure 2. Ef ect of the 1/ il 3 on the MDA-MB-231 cell cycle. DNA profiles of MDA-MB-231
cells following 72 h of culture t l iti (re line in A,B) and in the presence of either
10 µM 1/2 cocktail ( r li i ) r µ ( reen line in B). Cell distribution in the different cycle
phases is reported in the Table (annex).
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Literature reports indicate that drug-induced G2/M arrest of MDA-MB-231 cells is consistently
associated with apoptosis promotion (e.g., [13]); on the other hand, an increase of the sub-G0/G1 cell
fraction, consistent with the occurrence of apoptosis-triggered fragmentation of DNA, was observed at
the left of the G0/G1 peak in both treated conditions. To assess if the cytotoxicity of the 1/2 cocktail
and 3 were to be ascribed, at least in part, to the onset of programmed cell death, control and exposed
cells were submitted to flow cytometric evaluation of apoptosis and mitochondrial metabolism markers.
The panel in Figure 3 shows that, compared to controls, exposure to the drugs was associated with an
increase of annexin V+/propidium iodide- (Figure 3A) and activated caspase-8+ (Figure 3B) apoptotic
cells. In particular, 3 appeared to be more effective than the 1/2 cocktail in promoting phosphatydilserine
externalization (3 vs. 1/2 cocktail vs. control = 63.85% vs. 8.21% vs. 0.03%), whereas the extent of the
enzyme activation between the two experimental conditions was more comparable (3 vs. 1/2 cocktail
vs. control = 24.66% vs. 20.83% vs. 1.34%). Variations of MMP after cell exposure to the drugs were
detected using the JC1 probe. As shown in Figure 4, flow cytometry analysis suggests a loss of MMP
in treated cells, in particular 3-exposed cells to a higher extent, with the percentage of low red-emitting
cells (bottom quadrants) being about 61% and 75% after 72 h of exposure to the 1/2 cocktail and 3,
respectively, vs. approximately 35% of control cells.
The ability of the drugs to affect the mitochondrial metabolism was also checked by assaying
ROS production using a commercial kit, which differentiates between total ROS and superoxide ions.
As shown in Figure 5, the dissipation of MMP was mirrored by an enhanced production of ROS
(3 vs. 1/2 cocktail vs. control = 9.66% vs. 8.41% vs. 0.94%) including a more moderate increase of the
superoxide anion (3 vs. 1/2 cocktail vs. control = 2.75% vs. 3.43% vs. 0.6%).
Int. J. Mol. Sci. 2016, 17, 1235 4 of 10 
 
Literature reports indicate that drug-induced G2/M arrest of MDA-MB-231 cells is consistently 
associated with apoptosis promotion (e.g., [13]); on the other hand, an increase of the sub-G0/G1 cell 
fraction, consistent with the occurrence of apoptosis-triggered fragmentation of DNA, was observed 
at the left of the G0/G1 peak in both treated conditions. To assess if the cytotoxicity of the 1/2 cocktail and 
3 were to be ascribed, at least in part, to the onset of programmed cell death, control and exposed cells 
were submitted to flow cytometric evaluation of apoptosis and mitochondrial metabolism markers. 
The panel in Figure 3 shows that, compared to controls, exposure to the drugs was associated with  
an increase of annexin V+/propidium iodide- (Figure 3A) and activated caspase-8+ (Figure 3B) 
apoptotic cells. In particular, 3 appeared to be more effective than the 1/2 cocktail in promoting 
phosphatydilserine externalization (3 vs. 1/2 cocktail vs. control = 63.85% vs. 8.21% vs. 0.03%), whereas 
the extent of the enzyme activation between the two experimental conditions was more comparable  
(3 vs. 1/2 cocktail vs. control = 24.66% vs. 20.83% vs. 1.34%). Variations of MMP after cell exposure to 
the drugs were detected using the JC1 probe. As shown in Figure 4, flow cytometry analysis 
suggests a loss of MMP in treated cells, in particular 3-exposed cells to a higher extent, with the 
percentage of low red-emitting cells (bottom quadrants) being about 61% and 75% after 72 h of 
exposure to the 1/2 cocktail and 3, respectively, vs. approximately 35% of control cells. 
The ability of the drugs to affect the mitocho  lis  was also checked by assaying 
ROS production using a commercial kit, w ich differentiates between total ROS and superoxide 
ions. As shown in Figure 5, the dissipation of MMP was mirrored by an e  production of ROS 
(3 vs. 1/2 cocktail vs. control = 9.66  vs. 8.41  vs. 0.94 ) including a more moderate increase of the 
superoxide anion (3 vs. 1/2 cocktail vs. control = 2.75% vs. 3.43% vs. 0.6%). 
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MDA-MB-231 cells (C,F) stained with annexin V-FITC and propidium iodide for phosphatydilserine 
externalization (A–C), and with FAM-LETD-FMK caspase-8 reagent for caspase-8 activation (D–F). 
The percentage in the quadrants of plots A, B and C relates to late apoptotic/necrotic annexin 
V+/propidium iodide+ cells (top right quadrant) and early apoptotic annexin V+/propidium iodide− cells 
(bottom right quadrants). The percentage indicated in the quadrants of plots D, E and F refers to late 
apoptotic/necrotic cells (top right quadrants) and early apoptotic cells (bottom right quadrants) with 
activated caspase-8. 
 
Figure 3. Flow cytometric analysis of control (A,D), 1/2 cocktail–treated (B,E) and 3-treated
MDA-MB-231 cells (C,F) stained with annexin V-FITC and propidium iodide for phosphatydilserine
externalization (A–C), and with FAM-LETD-FMK caspase-8 reagent for caspase-8 activation (D–F).
The percentage in the quadrants of plots A, B and C relates to late apoptotic/necrotic annexin
V+/propidium iodide+ cells (top right quadrant) and early apoptotic annexin V+/propidium
iodide´ cells (bottom right quadrants). The percentage indicated in the quadrants of plots D, E
and F refers to late apoptotic/necrotic cells (top right quadrants) and early apoptotic cells (bottom right
quadrants) with activated caspase-8.
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It has been reported that MDA-MB-231 cells have a constitutively high autophagy rate [14], thereby
providing cells with energy and basic elements to counterbalance the metabolic stress associated with
hypoxia and nutrient shortage and fast proliferation. It is also acknowledged that the inhibition of
autophagy sensitizes MDA-MB-231 tumor cells to the lethal effect of chemical and physical agents
(e.g., [15,16]). Therefore, in a last set of analyses, we checked whether 1/2 cocktail and 3 might induce a
modification of the amount of autolysosomes, also known as AVOs, a hallmark of autophagy, through
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acridine orange staining. Interestingly, Figure 6 shows that 1/2 cocktail–treated cells underwent a
consistent reduction of AVO accumulation, whereas their amount in 3-treated cells was comparable to
that of the control (3 vs. 1/2 cocktail vs. control = 96.89% vs. 79.05% vs. 98.23%).
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The flow cytometric result was confirmed by a reduction in the amount of beclin-1, an essential
mediator involved in autophagy machinery, in MDA-MB-231 cells exposed to the 1/2 cocktail, as
visualized by Western blot (Figure 7). This revealed autophagy inhibition as a possible further aspect,
alternative to apoptotic induction, the level of which was lower than in 3-treated cells, involved in the
cytotoxicity exerted by the drug cocktail on the TNBC cell line.
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to their IC50 at 72 h, as already reported [3]. Several previous studies have confirmed the synergistic
effects of drugs used in combination as potential anticancer agents. For example, Zhang et al. [18] have
shown that a combination of Vorinostat (SAHA, 1) and the antiangiogenic kinase inhibitor Sorafenib,
acting on RAF kinase and the VEGFR-2/PDGFR-β pathway, exhibited in vivo synergism on death
induction in different tumor cytotypes. Since their findings suggested the activation of the extrinsic
apoptotic pathway, in order to assess the biological aspects of the cytotoxicity of the compounds under
study, it prompted us to examine whether this could also be the mode of action of the 1/2 cocktail
and/or 3. Preliminarily, cell cycle analysis showed a perturbation of the rate of progression through
the cycle, with aspects of redistribution of cells over different cycle phases for the two treatments,
and a significant increase of the sub-G0/G1 cell population, indicative of DNA fragmentation which
might occur in apoptotic cells, after exposure to both the cocktail and the hybrid. The annexin-V assay
confirmed that apoptosis was promoted by exposure to the drugs, more prominently in the case of
hybrid 3, and the observed caspase-8 activation was suggestive of the occurrence of receptor-mediated
death signaling [19]. Interestingly, both treatments were effective in inducing the dissipation of
MMP, also in this case more prominently in the presence of 3, and augmenting the levels of ROS,
which are classically considered as crucial events in the intrinsic mitochondria-mediated pathway of
apoptosis [20]. It is currently acknowledged that caspase-8 may stimulate the mitochondrial pathway
of apoptosis via the proteolytic maturation of BH3 interacting-domain death agonist (BID) protein,
thereby promoting the permeabilization of the outer mitochondrial membrane and the release of
cytochrome c [21,22]. On the other hand, the co-existence of both apoptotic pathways in MDA-MB-231
after treatment with a plant metabolite has been reported [23]. Thus, whether exposure especially
to 3 induces apoptosis in MDA-MB-231 cells by converging the death receptor-mediated extrinsic and
the mitochondrial intrinsic pathways, although plausible, remains to be determined through further
assays. Nevertheless, our cumulative results imply a higher efficacy of 3 in triggering programmed
cell death on TNBC cells.
Autophagy is a cellular homeostatic function in which cells autodigest cytoplasmic substrates
for removal or turnover after sequestration in multi-membrane-bound structures, the autophagic
vacuole, and subsequent fusion with lysosomes generating AVOs or autolysosomes [24]. It plays
a complex and highly controversial role in breast cancer: on one hand, autophagy can result in
cell death, thereby acting as a tumor-suppressor mechanism, but on the other hand, it can exert a
cell-protective role via intracellular recycling, providing energy and basic elements which allow tumor
cell survival in stress conditions of oxygen and nutrient shortage and rapid proliferative rate [25].
The latter pro-survival role appears to be the effect of the constitutively-elevated autophagy rate of
MDA-MB-231 cells [14]. In fact, various publications have demonstrated that inhibition of autophagy
in this cell line leads to sensitization to the lethal effect of chemicals and apoptosis activation [14,26,27].
In this paper we have checked whether the drugs under study might modulate the autophagic rate by
two different approaches, i.e., the flow cytometric evaluation of AVO accumulation in conjunction with
the immunorevelation of the protein marker beclin-1 [28], which is a key component of autophagy
machinery belonging to the signal-initiating class III phosphatidylinositol-3 kinase complex [29].
Interestingly, down-regulation of autophagy appeared to be most prominently triggered by the
1/2 cocktail, thus suggesting that the two forms of the examined compounds could induce cell death by
different preferential pathways, i.e., autophagy inhibition (1/2 cocktail) or apoptosis promotion (3).
It is noteworthy that a preliminary evaluation of the individual IC50 of either 1 or 2 after 72 h of
exposure revealed a different potency of the two compounds on MDA-MB-231 cells (approximately
1 µM for 1 [30] and 100 µM for 2), thereby indicating that equipotent co-treatment could have been
performed with a 1:100 1/2 cocktail. Surprisingly, this formulation was not able to induce more than
about 20% cell loss at the highest concentrations tested (Luparello, unpublished data) and therefore an
equimolar mixture of the drugs (10 µM for both), i.e., the same used in our previous publication [3],
was used in the present study. Thus, it can be hypothesized that excess 1 might be responsible for the
more marked G2/M arrest and involvement of apoptosis induced by treatment with 1:1 1/2 cocktail,
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in light of previous studies on the effects of SAHA on MDA-MB-231 cell cycle distribution [31]
and viability reduction due to activation of programmed cell death [32,33]. In particular, consistent
with our findings from these studies, both apoptotic pathways appeared to be triggered, since the
studies [32] demonstrated the activation of the intrinsic apoptotic pathway and the occurrence of
caspase-3 cleavage, whereas others [33] reported the upregulation of genes associated with the extrinsic
apoptotic pathway, such as TNF-related apoptosis-inducing ligand (TRAIL) and caspase-8 among
the others.
In conclusion, our results further substantiate the impressive potential of the hybrid vs.
combination approach in finely tuning the biological activities of target cells and also strongly
encourage the further optimization of 3-like molecules to develop a promising additional prevention
and/or treatment agent effective against “aggressive” breast carcinomas, such as TNBC.
4. Materials and Methods
4.1. Cell Culture and Drug Treatments
MDA-MB-231 breast cancer cells, were available in laboratory stocks and already used for study in
our lab (e.g., [14]), were maintained in a RPMI 1640 medium (Sigma, St. Louis, MO, USA) supplemented
with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotics (v/v) (100 U/mL penicillin, 100 µg/mL
streptomycin and 2.5 mg/L amphotericin B (Invitrogen, Carlsbad, CA, USA)) in a humidified
atmosphere at 37 ˝C in 5% CO2. Cells were detached from flasks with 0.05% trypsin-EDTA, counted,
and plated at the required density for treatment once 60%–80% confluency was attained.
The HDACi 1 was purchased from Selleck Chemicals, compounds 2 and 3 were synthesized as
reported [34].
In light of the values of IC50 at 72 h already reported for 1:1 1/2 cocktail and for 3 [3], the biological
assays were performed in the presence of either 10 µM of the 1/2 cocktail or 29 µM of 3. Control
cells were exposed to dimethyl sulphoxide, (Santa Cruz Biotechnology, Dallas, TX, USA) at the
same concentrations.
4.2. Flow Cytometry
Flow cytometric assays were performed according to Librizzi et al. [14].
MMP was verified by use of a fluorescent dye JC1 (Molecular Probes, Eugene, OR, USA), which is
selectively taken up into mitochondria, leading to a fluorescence emission shift from green (~529 nm)
to red (~590 nm) for intact MMP, although in the case of mitochondrial depolarization a decrease in the
red/green fluorescence intensity ratio is observed. The ionophore valinomycin (Sigma), which induces
mitochondrial gradient dissipation, was co-incubated at 1 µM concentration with JC1 for positive
control. Data were represented as dot plots using Flowing Software v.2.5.1. (Mr. Perttu Terho, Turku
Centre for Biotechnology, Turku, Finland), which discriminate, in the bottom quadrants, the amount of
cells undergoing a loss of MMP.
Quantification of AVOs was obtained via acridine orange staining (Sigma, final concentration
of 100 µg/mL) for 20 min (in the dark) prior to analysis. Data are displayed as dot-plots using the
Flowing software v.2.5.1., which is able to discriminate cells with increased AVO accumulation in the
top quadrants.
Cell cycle distribution was checked using propidium iodide stain following pre-incubation with
Triton X-100 and RNase A (Sigma), and analyzed with Weasel v.3.0.1. software (Murray Jeffs, Walter &
Eliza Hall Institute of Medical Research, Parkville, Australia).
Activation of caspase-8 was assessed with a Vybrant FAM caspase-8 assay kit (Molecular Probes)
following the manufacturer’s instructions. Data are represented as dot-plots with Flowing software
v.2.5.1., which discriminates early and late apoptotic cells with increased enzyme activation in the
bottom and top right quadrants, respectively.
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All the preparations assayed contained both attached and floating cells, and all the analyses were
carried out in a FACSCanto apparatus (BD Biosciences, Franklin Lakes, NJ, USA).
4.3. Western Blot
Electrophoretic analyses and immunoblots were carried out according to Librizzi et al. [35].
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Abbreviations
HDACi histone deacetylase inhibitor
SAHA suberoylanilide hydroxamic acid
VEGFR1/2i vascular endothelial growth factor-1 and -2 receptor inhibitor
TNBC triple-negative breast cancer
EGFR epidermal growth factor receptor
VEGFR vascular endothelial growth factor receptor
PI3K phosphatidylInositol 3-kinase
STAT3 signal transducer and activator of transcription 3
IC50 half maximal inhibitory concentration
MMP mitochondrial transmembrane potential
ROS reactive oxygen species
AVO acidic vesicular organelle
PDGFR platelet-derived growth factor receptors
BID BH3 interacting-domain death agonist
TRAIL TNF-related apoptosis-inducing ligand
FBS fetal bovine serum
EDTA ethylenediaminetetraacetic acid
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
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